Company intelligence / Profile preview

Telos

Dallas, Texas, United States

Ownership: Private
Development stage: Other

Overview

Telos Biotech emerged from stealth mode in 2023 and is developing Telovance, a novel recombinant protein designed to lengthen the shortest telomeres rapidly and safely during ex-vivo cell therapy manufacturing. The technology aims to overcome cell aging and replicative lifespan limits caused by critically short telomeres, particularly in CAR T-cell immunotherapy.

Therapeutic areas: OncologyOther
Modalities: Recombinant proteinCell therapy
Industry: Biotech

Partnerships

Cell therapy manufacturing companies

Beyond the preview

Go deeper on Telos.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Telos.

Explore the full profile